Main Article Content

Fahmida Naheed
Sumaira Khoso
Amjid Azam Sirewal
Ghazala Shaheen
Momna Khan


Gestational Diabetes Mellitus (GDM), Myo-Inositol, Pregnancy, Supplementation, BMI


Objective: To evaluate the incidence of gestational diabetes mellitus (GDM) among pregnant women at risk following the administration of Myo-Inositol in comparison to a placebo.

Study design: A randomized controlled trial

Place and Duration This study was conducted in Bolan Medical Complex Hospital Quetta from September 2022 to September 2023.

Methodology: Regardless of parity, a total of 100 pregnant women in the first trimester who had  at least one first-degree relative with diabetes mellitus and who were overweight (BMI >25 kg/m2) or obese (BMI >30 kg/m2) at their first prenatal visit were participated. The women who met the exclusion criteria had already been diagnosed with diabetes mellitus. The intervention group got a daily dosage of 2g Myo-Inositol and 200 mcg Folic acid starting from the end of the first trimester or the beginning of the second trimester (12–15 weeks of gestation), while the placebo group only received 200 mcg Folic acid twice daily. Every subject was tested for a 75gm 2-hour OGTT between 24 and 48 weeks.

Results: The mean age of the female participants in the intervention group was 27.45 ± 4.28 years, whereas it was 28.77 ± 4.26 years in the placebo group. The mean gestational age of the intervention group was 9.26 ± 1.89 weeks, whereas the mean gestational age of the placebo group was 9.48 ± 1.79 weeks. The study found that among at-risk parturient women using myo-inositol-containing supplements, the incidence of gestational diabetes mellitus was 17%, while in the placebo group, it was 37% (p-value, 0.01).

Conclusion: Supplementing with myo-inositol has been shown to lower the incidence of gestational diabetes mellitus in pregnant women who have been recognized as having risk factors.

Abstract 72 | Pdf Downloads 26


1. Di Guardo F, Currò JM, Valenti G, Rossetti P, Di Gregorio LM, Conway F, Chiofalo B, Garzon S, Bruni S, Rizzo G. Non-pharmacological management of gestational diabetes: The role of myo-inositol. Journal of Complementary and Integrative Medicine. 2020 Jun 1;17(2).
2. D’ANNA R, Santamaria A, Alibrandi A, Corrado F, DI BENEDETTO A, Facchinetti F. Myo-inositol for the prevention of gestational diabetes mellitus. A brief review. Journal of nutritional science and vitaminology. 2019 Oct 11;65(Supplement):S59-61.
3. Brown J, Crawford TJ, Alsweiler J, Crowther CA. Dietary supplementation with myo‐inositol in women during pregnancy for treating gestational diabetes. Cochrane Database of Systematic Reviews. 2016(9).
4. Godfrey KM, Barton SJ, El-Heis S, Kenealy T, Nield H, Baker PN, Chong YS, Cutfield W, Chan SY. Myo-inositol, probiotics, and micronutrient supplementation from preconception for glycemia in pregnancy: NiPPeR International Multicenter Double-Blind Randomized Controlled Trial. Diabetes Care. 2021 May 1;44(5):1091-9.
5. Fatima K, Jamil Z, Faheem S, Adnan A, Javaid SS, Naeem H, Mohiuddin N, Sajid A, Ochani S. Effects of myo-inositol vs. metformin on hormonal and metabolic parameters in women with PCOS: a meta-analysis. Irish Journal of Medical Science (1971-). 2023 May 6:1-8.
6. Rabeet M, Baig AA, Khan AA. A Comparative Study of Myo Inositol Versus Metformin in Improving Symptoms of Menstrual Irregularities in Polycystic Ovarian Syndrome Women. Annals of the Romanian Society for Cell Biology. 2023 Jan 4;27(01):275-81.
7. Crawford TJ, Crowther CA, Alsweiler J, Brown J. Antenatal dietary supplementation with myo‐inositol in women during pregnancy for preventing gestational diabetes. Cochrane Database of Systematic Reviews. 2015(12).
8. Farren M, Daly N, McKeating A, Kinsley B, Turner MJ, Daly S. The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes care. 2017 Jun 1;40(6):759-63.
9. Tahir F, Majid Z. Inositol supplementation in the prevention of gestational diabetes mellitus. Cureus. 2019 Sep 16;11(9).
10. D’Anna R, Scilipoti A, Giordano D, Caruso C, Cannata ML, Interdonato ML, Corrado F, Di Benedetto A. myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes care. 2013 Apr 1;36(4):854-7.
11. Matarrelli B, Vitacolonna E, D’angelo M, Pavone G, Mattei PA, Liberati M, Celentano C. Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial. The Journal of Maternal-Fetal & Neonatal Medicine. 2013 Jul 1;26(10):967-72.
12. Mashayekh-Amiri S, Mohammad-Alizadeh-Charandabi S, Abdolalipour S, Mirghafourvand M. Myo-inositol supplementation for prevention of gestational diabetes mellitus in overweight and obese pregnant women: a systematic review and meta-analysis. Diabetology & Metabolic Syndrome. 2022 Dec;14(1):1-5.
13. Santamaria A, Di Benedetto A, Petrella E, Pintaudi B, Corrado F, D’Anna R, Neri I, Facchinetti F. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. The Journal of Maternal-Fetal & Neonatal Medicine. 2016 Oct 1;29(19):3234-7.
14. Majeed R, Mobashar S, Sher Z, Jan S, Mumtaz H. Is Myo-inositol better than Metformin for treatment of PCOS Overweight Patients?. Journal of The Society of Obstetricians and Gynaecologists of Pakistan. 2021 Oct 12;11(3):195-9.
15. Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013 Oct 1;95(10):1811-27.
16. Facchinetti F, D’Anna R, Hod M. Inositol supplementation for preventing gestational diabetes mellitus. InA Clinical Guide to Inositols 2023 Jan 1 (pp. 123-150). Academic Press.
17. Nachum Z, Zafran N, Salim R, Hissin N, Hasanein J, Gam Ze Letova Y, Suleiman A, Yefet E. Glyburide versus metformin and their combination for the treatment of gestational diabetes mellitus: a randomized controlled study. Diabetes care. 2017 Mar 1;40(3):332-7.